Tuberculosis (TB) is still the number one cause of death due to an infectious disease.
Pharmacokinetics and pharmacodynamics of anti-TB drugs are key in the optimization of TB …

Pyrazinamide is a first-line tuberculosis drug with potent sterilizing activity. Variability in drug
exposure may potentially translate into suboptimal treatment responses. This systematic …

Pyrazinamide is one of the first-line antituberculosis drugs. The efficacy of pyrazinamide is
associated with the ratio of 24-h area under the concentration–time curve (AUC24) to MIC …

Rationale: Optimizing pyrazinamide dosing is critical to improve treatment efficacy while
minimizing toxicity during tuberculosis treatment. Study 31/AIDS Clinical Trials Group A5349 …

Objectives: This study was performed to develop a population pharmacokinetic model of
pyrazinamide for Korean tuberculosis (TB) patients and to explore and identify the influence …

Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains a leading cause of
death with 1.6 million deaths worldwide reported in 2021. Oral pyrazinamide (PZA) is an …

Pyrazinamide is a first-line drug used in the treatment of tuberculosis. High exposure to
pyrazinamide and its metabolites may result in hepatotoxicity, whereas low exposure to …

Tuberculosis (TB) is a leading cause of mortality worldwide, and resistance to anti-
tuberculosis drugs is a challenge to effective treatment. Multi-drug resistant TB (MDR-TB) …

Multidrug-resistant tuberculosis (MDR-TB) is becoming a global health crisis. The World
Health Organization has released new guidelines for the use of tuberculosis-active drugs for …

Introduction Ethionamide is part of the drug‐resistant tuberculosis regimen whose
pharmacokinetic (PK) and pharmacodynamic (PD) information is limited. The aim of the …